Rocatinlimab in prurigo nodularis · n=469
Reason given: Sponsor Decision
Rocatinlimab in asthma · n=317
Reason given: Sponsor Decision
HZN-1116 in sjogren's syndrome · n=209
Reason given: The study was terminated by sponsor due to meeting pre-defined criteria for futility.
Romiplostim in severe aplastic anemia (saa) · n=0
Reason given: Operational
Rocatinlimab in atopic dermatitis · n=2621
Reason given: Sponsor Decision
Efavaleukin alfa in ulcerative colitis · n=25
Reason given: The parent study 20170104 was terminated due to the study meeting a prespecified futility rule. Consequently, this study was terminated.
Daxdilimab in lupus nephritis · n=19
Reason given: Sponsor Decision
Placebo in discoid lupus erythematosus · n=72
Reason given: Sponsor business decision, not related to safety concerns.
HZN-825 in diffuse cutaneous systemic sclerosis · n=174
Reason given: The study was not stopped due to safety reasons
Bemarituzumab in solid tumors · n=260
Reason given: Sponsor Decision
Daxdilimab in systemic lupus erythematosus · n=155
Reason given: Sponsor Decision
Bemarituzumab in gastric cancer · n=72
Reason given: Sponsor Decision
Bemarituzumab in gastric cancer · n=515
Reason given: Study was terminated by sponsor
Efavaleukin alfa in ulcerative colitis · n=221
Reason given: The study was terminated due to meeting a prespecified futility rule and not related to any safety concerns.
Sotorasib in non-small cell lung cancer · n=42
Reason given: Futility
HZN-825 in idiopathic pulmonary fibrosis · n=153
Reason given: The trial was terminated due to not meeting primary or key secondary endpoints.
HZN-825 BID in diffuse cutaneous systemic sclerosis · n=301
Reason given: The study was terminated due to meeting pre-defined criteria for futility.
ABP 215 in metastatic non-small cell lung cancer (nsclc) · n=0
Reason given: Sponsor decision to early terminate the study
Efavaleukin Alfa in active systemic lupus erythematosus · n=168
Reason given: The trial was terminated prematurely as it met pre-defined criteria for futility at IA3.
Acapatamab in metastatic castration-resistant prostate cancer · n=55
Reason given: Amgen made a business decision to discontinue all AMG 160 clinical trials. This decision is not related to safety.
Inebilizumab in highly sensitized patients on waiting list for kidney transplantation · n=0
Reason given: Stopped due to no enrollment
evolocumab in primary hypercholesterolemia · n=259
Reason given: Prematurely Discontinued Amgen decision
Tezepelumab in atopic dermatitis · n=251
Reason given: Tezepelumab as a monotherapy in atopic dermatitis did not reach the targeted efficacy level pre-established for this patient population.
Ivabradine in heart transplantation, elevated resting heart rate · n=0
Reason given: Sponsor decision
CCX140-B in focal segmental glomerulosclerosis · n=5
Reason given: Program not advancing
Denosumab in osteogenesis imperfecta (oi) · n=75
Reason given: The study was stopped earlier than planned due to safety concerns about high levels of calcium in the blood of the participants
Dexamethasone in relapsed or refractory multiple myeloma · n=7
Reason given: Sponsor Decision
Blinatumomab in high-risk diffuse large b-cell lymphoma · n=10
Reason given: Early Closure due to rare patient population
Efavaleukin alfa in rheumatoid arthritis ra · n=36
Reason given: Amgen made a business decision not to proceed with Phase 2.
Efavaleukin Alfa in chronic graft versus host disease cgvhd · n=32
Reason given: Sponsor Decision
Romiplostim in chemotherapy-induced thrombocytopenia · n=0
Reason given: Study was not feasible
Evolocumab in dyslipidemia · n=1600
Reason given: Amgen business decision to close study early
OIPhase 3 · started 2015 · terminated Denosumab in osteogenesis imperfecta · n=153
Reason given: The study was stopped earlier than planned due to safety concerns about high levels of calcium in the blood of the participants
Cysteamine Bitartrate in mitochondrial diseases · n=22
Reason given: Sponsor decision to end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001.
Brodalumab 210 mg in axial spondyloarthritis · n=0
Reason given: Per Amgen's decision to discontinue co-development and co-commercialization of brodalumab, study is being cancelled/closed.
Talimogene Laherparepvec in melanoma · n=713
No reason recorded in the registry.
Oprozomib in advanced hepatocellular carcinoma · n=0
Reason given: Study stopped due to administrative reasons
Cinacalcet HCl in chronic kidney disease, secondary hyperparathyroidism · n=55
Reason given: Amgen decided to terminate the study early to be able to meet US regulatory timelines fo filing. Subjects in treatment were rolled over to the 20140159 study.
Rilotumumab in gastric cancer · n=34
Reason given: All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data Monitoring Committee safety review of study 20070622.
AMG 337 in stomach neoplasms · n=60
Reason given: Amgen decision following interim review of efficacy and safety data from the AMG 337 program.
Blinatumomab in relapsed/refractory b-precursor acute lymphoblastic leukemia · n=405
No reason recorded in the registry.
Oprozomib in multiple myeloma · n=22
Reason given: A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in OPZ003 was halted during dose-escalation.
Oprozomib in multiple myeloma · n=65
Reason given: Enrollment halted during phase 2 to reformulate the investigational product
Placebo in asthma · n=421
Reason given: Study terminated early due to lack of efficacy observed following interim analysis in Q2 2015. Study Closed once all sites were closed in eClinical
Rilotumumab in gastric cancer · n=609
Reason given: All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data Monitoring Committee safety review of study 20070622.
Cinacalcet hydrochloride in chronic kidney disease · n=18
Reason given: Amgen decided to terminate the study early to be able to meet US regulatory timelines fo filing. Subjects in treatment were rolled over to the 20140159 study.
AMG 747 in schizophrenia · n=121
Reason given: Toxic Epidermal Necrolysis
AMG 747 in schizophrenia · n=111
Reason given: Toxic Epidermal Necrolysis
AMG 386 in fallopian tube cancer · n=1015
Reason given: Amgen Administrative Decision - termination of LTFU
oprozomib in multiple myeloma · n=210
Reason given: A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in 2011-001 was halted.
cinacalcet capsule in chronic kidney disease · n=43
Reason given: Study was put on clinical hold on 30 Jan 2013 following a subject fatality. Study was never restarted and was closed.
AMG386 plus PLD in fallopian tube cancer · n=223
Reason given: Closure of long term follow up (LTFU) and study earlier than previously outlined in the protocol as no beneficial information gained from continuing LTFU.
Brodalumab in crohn's disease · n=67
Reason given: The study was terminated early based on an imbalance in worsening Crohn's disease in active treatment groups.
Apremilast 30 mg in rheumatoid arthritis · n=237
Reason given: Study is terminated due to lack of efficacy
Brodalumab in crohn's disease · n=130
Reason given: The study was terminated early based on an imbalance in worsening Crohn's disease in active treatment groups
AMG 827 in rheumatoid arthritis · n=211
Reason given: Lack of efficacy for Brodalumab in Rheumatoid Arthritis (RA)
Placebo in breast cancer · n=4509
Reason given: Terminated: Amgen decision following Primary Analysis. Not due to safety reason
AMG 745 0.3 mg/kg in age-associated muscle loss · n=0
Reason given: Amgen has chosen at this time not to continue with AMG 745 study 20080733
Darbepoetin alfa in non-small cell lung cancer · n=2549
No reason recorded in the registry.
Darbepoetin Alfa in anemia · n=116
Reason given: FDA and EMA agreed that the information that had been submitted to date was acceptable to meet the requirements of the post-marketing commitment.
AMG 108 in diabetes mellitus · n=0
Reason given: Program Development discontinued
sodium phenylacetate and sodium benzoate injection 10% / 10% in hepatic encephalopathy · n=1
Reason given: Study was terminated due to lack of enrollment and business decisions.
AMG 706 in non-small cell lung cancer · n=1450
Reason given: Amgen discontinued the development of AMG706 because 20050201 did not meet its primary objective.
Bevacizumab in advanced non-squamous nsclc · n=186
No reason recorded in the registry.
Placebo in anemia · n=12
Reason given: Study terminated
Gemcitabine in cancer of pancreas · n=3
Reason given: APPRISE closure prompted by SWOG S0205 not meeting primary endpoint-improving OS. APPRISE enrollment closure due to similar design;no unexpected safety data
AMG 706 placebo in breast neoplasms · n=282
Reason given: Sponsor decision to close study
Darbepoetin alfa in anemia · n=51
Reason given: The reason for the discontinuation of the study is difficulty with recruitment and timely enrolment and is not related to safety concerns
AMG 706 in solid tumors · n=94
Reason given: Amgen decision
Epoetin alfa DT in chronic kidney disease · n=850
Reason given: Regulatory decision not to proceed
darbepoetin alfa in anemia · n=287
Reason given: slow enrollment and change in product development strategy
anakinra in rheumatoid arthritis · n=22
Reason given: The safety profile of combination therapy became unacceptable.
Etanercept in juvenile rheumatoid arthritis · n=19
Reason given: the study was terminated because of slow enrollment
Etanercept in juvenile rheumatoid arthritis · n=25
No reason recorded in the registry.
AMG 114 in anemia
No reason recorded in the registry.